The characterization of dysphagia in COVID ‐19 rehabilitation patients: An inpatient rehabilitation cohort study
PM&R · 2026
DOI: 10.1002/pmrj.70113 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PM&R, 2026. Verfasst von Benjamin K Petrie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shirley Ryan AbilityLab, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Deglutition Disorders, COVID-19, Rehabilitation Centers, Inpatients. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Catalyst Grant from the Shirley Ryan AbilityLab, National Institute of Aging, Claude Pepper Center.
Themen: Dysphagie
Abstract (Originalsprache)
Background
Severe COVID‐19 infection requiring hospitalization is associated with oropharyngeal dysphagia, yet trajectories in the inpatient rehabilitation facility (IRF) setting remain undercharacterized.
Objective
To investigate the prevalence, risk factors, recovery likelihood, and evolution of dietary requirements of patients with dysphagia due to severe COVID‐19 infection admitted to IRF.
Design
Retrospective cohort study.
Setting
Three free‐standing urban IRFs. Patients Two hundred forty eight patients with acute symptomatic COVID‐19 admitted to IRF between April 2020 and February 2021. Dysphagia was defined by abnormalities on videofluoroscopic swallow study, Functional Oral Intake Scale, or Mann Assessment of Swallowing Ability. Patients with neurologic disease, nil per os status on IRF admission, or indeterminate dysphagia status were excluded.
Interventions
Multidisciplinary IRF dysphagia treatment, per standard of care. Main outcome measures Dysphagia prevalence and resolution, dietary consistencies, and Functional Independence Measure scores.
Results
Of the included patients, 46.0% had dysphagia on admission ( n = 114), most commonly oropharyngeal (89.7%), followed by oral (8.6%) and pharyngeal (1.7%). Dysphagia resolved during an average 3‐week IRF stay in 43.5% of cases. Higher Functional Independence Measure comprehension scores were associated with lower likelihood of dysphagia ( p = .002) and higher likelihood of resolution ( p = .021). Discharge to home was common in both those with persistent and resolved dysphagia (86.5% vs. 88.6%). Additionally, 92.1% ( n = 105) of patients with dysphagia on admission were discharged on a normal or International Dysphagia Diet Standardisation Initiative Level 6/0 diet.
Conclusions
In this large study of dysphagia in patients with COVID‐19 requiring IRF, a strong, novel association between cognitive function and both dysphagia incidence and recovery was observed in patients without discrete neurologic injury. Although persistent dysphagia was common at discharge, most patients transitioned to a normal or near‐normal diet.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Shirley Ryan AbilityLab, Chicago, Illinois, USA.
- Department of Physical Medicine & Rehabilitation, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Biomedical Informatics & Medical Education, University of Washington Medicine, Seattle, Washington, USA.
ORCID-Profile: Benjamin K Petrie, Sean Dreyer, Prakash Jayabalan
Förderung
- NIA NIH HHS
- Catalyst Grant from the Shirley Ryan AbilityLab
- National Institute of Aging, Claude Pepper Center
Zitieren
APA
Petrie, B. K., Lewis, C. W., Dreyer, S., & Jayabalan, P. (2026). The characterization of dysphagia in COVID ‐19 rehabilitation patients: An inpatient rehabilitation cohort study. PM&R. https://doi.org/10.1002/pmrj.70113
Vancouver
Petrie BK, Lewis CW, Dreyer S, Jayabalan P. The characterization of dysphagia in COVID ‐19 rehabilitation patients: An inpatient rehabilitation cohort study. PM&R. 2026. doi:10.1002/pmrj.70113
BibTeX
@article{Petrie2026,
author = {Petrie, Benjamin K and Lewis, Christopher W and Dreyer, Sean and Jayabalan, Prakash},
title = {The characterization of dysphagia in COVID ‐19 rehabilitation patients: An inpatient rehabilitation cohort study},
journal = {PM&R},
year = {2026},
doi = {10.1002/pmrj.70113}
}
EUVIMED